Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501

Rocket Pharmaceuticals, Inc. announced that the US FDA has lifted the clinical hold on the company’s Phase I clinical trial of RP-A501 for the treatment of Danon Disease, allowing patient enrollment to resume. RP-A501 is an investigational gene therapy product being developed for Danon Disease and the first potential gene therapy for monogenic heart failure.